![]() Approval: 1979 INDICATIONS AND USAGE. A safe and effective dose has not been established in the pediatric population. Safety of transdermal scopolamine in pediatric patients for chemotherapy-induced nausea and vomiting (CINV) L.Central anticholinergic syndrome in a pediatric patient following transdermal scopolamine patch placement. The scopolamine patch was promptly. A transdermal scopolamine patch should not be used in the pediatric. The use of transdermal scopolamine to control drooling. Although transdermal scopolamine may represent one acceptable facet. Scopolamine does cross the placenta. Pediatric Use The safety and effectiveness of Transderm Scop in. Scopolamine Dosage Guide with Precautions. Applies to the following strength(s): 1. L ; 0. 4 mg/m. L ; 0. The information at Drugs. Always consult your doctor or pharmacist. Usual Adult Dose for: Usual Pediatric Dose for: Additional dosage information: Usual Adult Dose for Nausea/Vomiting. General antiemetic use: 0. Find patient medical information for scopolamine transdermal on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. IV, intramuscularly or subcutaneously every 6 to 8 hours as needed. Post- operative nausea and vomiting use: apply one scopolamine 1. ![]() The disc should remain in place for 2. If using scopolamine transdermal on an obstetrics patient, apply the disc one hour prior to scheduled Cesarean section to limit exposure to the infant. Usual Adult Dose for Motion Sickness. Apply one scopolamine 1. Usual Adult Dose for Parkinsonian Tremor. Usual Pediatric Dose for Nausea/Vomiting. IV, IM or subcutaneous every 6 to 8 hours as needed. Usual Pediatric Dose for Motion Sickness. Greater than 1. 2 years: apply one scopolamine 1. Renal Dose Adjustments. Data not available. Liver Dose Adjustments. Data not available. Precautions. As with other anticholinergic agents, scopolamine is contraindicated for patients with angle- closure glaucoma, prostatic hypertrophy, and pyloric obstruction. It should not be administered to patients with impaired hepatic or renal function. Scopolamine may cause drowsiness, confusion, and disorientation. The elderly may be particularly sensitive to these effects. All patients should be cautioned against engaging in activities which require mental alertness, such as driving or operating dangerous machinery, while using the scopolamine transdermal patch. The concomitant use of alcohol or other agents possessing CNS depressant activity should be avoided if possible. Scopolamine may aggravate seizures (although this association has been disputed) and psychoses and should be used cautiously in patients with a history of such disorders. Use with caution in patients with cardiac disease and in the elderly. The safety and efficacy of scopolamine in children have not been determined. Dialysis. Data not available. Other Comments. Scopolamine transdermal patches contain residual drug when removed after being applied for 7. Patients should wash their hands well with soap and water to prevent accidental transfer of scopolamine to eyes or mucosal surfaces. Once removed, the patch should be folded against itself such that the adhesive side containing residual drug is not accessible. Only one transdermal patch should be on the patient at any given time during therapy; remove the used disc prior to placing a fresh disc on the skin. More about scopolamine Consumer resources Professional resources Related treatment guides. Central anticholinergic syndrome in a pediatric patient following transdermal scopolamine patch placement. Postoperatively, the child was placed on patient- controlled analgesia, with morphine as the drug of choice. The patient was discharged to the ward with adequate pain control and no complaints of nausea or vomiting. Once on the ward, a transdermal scopolamine patch was placed for nausea and vomiting. More than 2. 4 hours after patch placement, the child experienced central anticholinergic syndrome (CAS) with hallucinations and incontinence. The scopolamine patch was promptly removed, and all symptoms of CAS rapidly ceased. A transdermal scopolamine patch should not be used in the pediatric population, and with extreme caution in the elderly. Treatment of CAS includes prompt removal of the patch, cleansing of the area, and possible physostigmine administration.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
September 2016
Categories |